| Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine (NCT01086423) | GlaxoSmithKline | 2010-03-01 |
| Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) (NCT00964028) | GlaxoSmithKline | 2009-12-01 |
| Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age (NCT01031303) | Sanofi | 2009-12-01 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine (NCT01021293) | GlaxoSmithKline | 2009-11-28 |
| Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age (NCT00970307) | GlaxoSmithKline | 2009-08-13 |
| Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants (NCT00937404) | GlaxoSmithKline | 2009-08-04 |
| The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV) (NCT01056705) | Chinese Academy of Medical Sciences | 2009-07-01 |
| Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers (NCT00920439) | GlaxoSmithKline | 2009-06-01 |
| Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly (NCT00885157) | Sanofi Pasteur, a Sanofi Company | 2009-04-01 |
| Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. (NCT00871000) | GlaxoSmithKline | 2009-04-01 |
| Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. (NCT00871741) | GlaxoSmithKline | 2009-04-01 |
| Immunogenicity and Safety of Adacel Polio Vaccine (NCT00797511) | Sanofi | 2008-11-01 |
| Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants (NCT00753649) | GlaxoSmithKline | 2008-09-23 |
| The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (NCT01048190) | Chinese Academy of Medical Sciences | 2008-08-01 |
| Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ (NCT00654901) | Sanofi Pasteur, a Sanofi Company | 2008-03-01 |
| Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children (NCT00611559) | GlaxoSmithKline | 2008-02-14 |
| Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine (NCT00635128) | GlaxoSmithKline | 2008-02-01 |
| Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine (NCT00627458) | GlaxoSmithKline | 2008-02-01 |
| Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly (NCT00604058) | Sanofi Pasteur, a Sanofi Company | 2008-01-01 |
| Quality of Life in Adult Neurological Patients (NCT01573936) | Associação de Assistência a Criança Deficiente | 2008-01-01 |
| A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children (NCT00514033) | GlaxoSmithKline | 2007-07-01 |
| Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (NCT00463437) | GlaxoSmithKline | 2007-04-25 |
| Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months (NCT00453570) | Sanofi | 2007-03-01 |
| REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children (NCT00447525) | Sanofi Pasteur, a Sanofi Company | 2007-02-01 |
| Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) (NCT00432042) | Merck Sharp & Dohme LLC | 2007-01-12 |
| Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants (NCT00404651) | Sanofi Pasteur, a Sanofi Company | 2006-11-01 |
| Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age (NCT00376779) | GlaxoSmithKline | 2006-10-01 |
| Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® (NCT00355121) | Sanofi | 2006-10-01 |
| Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers (NCT00343421) | Sanofi Pasteur, a Sanofi Company | 2006-07-01 |
| Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV (NCT00348387) | Sanofi Pasteur, a Sanofi Company | 2006-06-01 |
| Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) (NCT00337428) | Merck Sharp & Dohme LLC | 2006-05-01 |
| Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV (NCT00319852) | Sanofi | 2006-04-01 |
| Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants (NCT00320463) | GlaxoSmithKline | 2006-04-01 |
| Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine (NCT00304265) | Sanofi Pasteur, a Sanofi Company | 2006-03-01 |
| Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants (NCT00287092) | Sanofi Pasteur, a Sanofi Company | 2006-02-01 |
| Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants (NCT00303316) | Sanofi | 2006-02-01 |
| Pentavalent DTaP-Hep B-IPV (NCT00133445) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-12-01 |
| Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand (NCT00255021) | Sanofi | 2005-12-01 |
| Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules (NCT00316147) | GlaxoSmithKline | 2005-12-01 |
| Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 (NCT00307567) | GlaxoSmithKline | 2005-11-01 |
| Safety of Imovax Polio in Chinese Infants and Children (NCT00258843) | Sanofi Pasteur, a Sanofi Company | 2005-11-01 |
| Immunogenicity and Safety of Pentaxim in South African Infants (NCT00254969) | Sanofi | 2005-10-01 |
| Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants (NCT00325156) | GlaxoSmithKline | 2004-11-02 |
| Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants (NCT00831311) | Sanofi Pasteur, a Sanofi Company | 2004-10-01 |
| Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine (NCT00325143) | GlaxoSmithKline | 2003-12-01 |
| Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course (NCT01457547) | GlaxoSmithKline | 2003-10-01 |
| Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). (NCT00352963) | GlaxoSmithKline | 2003-09-30 |
| Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine (NCT00146835) | GlaxoSmithKline | 2003-04-01 |
| Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) (NCT00092469) | Merck Sharp & Dohme LLC | 2002-03-01 |
| Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants (NCT00879827) | GlaxoSmithKline | 2000-09-01 |
| Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine (NCT01457560) | GlaxoSmithKline | 2000-02-01 |
| Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately (NCT01457508) | GlaxoSmithKline | 1999-01-01 |
| Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly (NCT01457495) | GlaxoSmithKline | 1998-09-01 |
| Study of "Post-Polio Syndrome" (NCT00001185) | National Institute of Neurological Disorders and Stroke (NINDS) | 1982-06-01 |
| Pilot Study Freeze and Transport Immune Cells (NCT00138268) | National Institute of Allergy and Infectious Diseases (NIAID) | |